NCT04643574View on ClinicalTrials.gov

NeoTIL in Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Solid Tumor, Adult
Interventions
BIOLOGICAL

NeoTIL

Adoptive transfer of ex vivo expanded Autologous Tumor-Infiltrating Lymphocytes enriched for tumor antigen specificity (NeoTIL)

DRUG

Cyclophosphamide

Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

DRUG

Fludarabine

Fludarabine will be administered as an intravenous (IV) infusion for five days.

DRUG

Interleukin-2

After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of fourteen doses.

RADIATION

Radiotherapy

Low-dose irradiation (1Gy) will be administered using tomotherapy to tumor lesions once before NeoTIL infusion.

Trial Locations (1)

1011

centre hospitalier universitaire vaudois (CHUV), Lausanne

All Listed Sponsors
lead

Centre Hospitalier Universitaire Vaudois

OTHER

NCT04643574 - NeoTIL in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter